Skip to main content
. 2020 Jul 3;12:1758835920937893. doi: 10.1177/1758835920937893

Table 2.

Cox proportional-hazards regression model for recurrence-free survival and overall survival in patients with lung adenocarcinoma ⩽2 cm presented as pure solid nodules (n = 772).

Variables Recurrence-free survival
Overall survival
Univariate
Multivariate
Univariate
Multivariate
p HR (95% CI) p p HR (95%CI) p
Age (>65 versus ⩽65) 0.483 0.327
Sex (male versus female) 0.108 0.216
Smoking (current or ex- versus non-smoker) 0.288 0.173
COPD (present versus absent) 0.348 0.006 1.055 (0.407–2.734) 0.913
Cardiovascular disease (present versus absent) 0.152 0.003 1.619 (0.652–4.02) 0.299
Diabetes mellitus (present versus absent) 0.182 0.225
FEV1% (>70 versus ⩽70) 0.842 0.957
CEA (>10 versus ⩽10 ng/ml) 0.068 1.41 (0.974–2.041) 0.220 0.095 1.248 (0.811–1.919) 0.314
VPI (present versus absent) 0.117 0.23
VATS (yes versus no) 0.631 0.188
Tumor location (upper and middle versus lower) 0.610 0.383
Surgical procedure
 Lobectomy (reference) reference reference reference reference
 Segmentectomy 0.131 1.266 (0.763–2.1) 0.361 0.019 1.448 (0.775–2.706) 0.246
 Wedge resection <0.001 2.252 (1.603–3.164) <0.001 <0.001 3.16 (2.154–4.635) <0.001
Percentage of MIP subtype (>5% versus ⩽5%) <0.001 1.704 (1.276–2.277) <0.001 <0.001 1.83 (1.291–2.595) 0.001
Percentage of solid subtype (>5% versus ⩽5%) 0.002 1.264 (0.939–1.702) 0.124 <0.001 1.458 (1.014–2.095) 0.042
Percentage of acinar subtype (>5% versus ⩽5%) 0.532 0.151
Percentage of papillary subtype (>5% versus ⩽5%) 0.369 0.936
Percentage of lepidic subtype (>5% versus ⩽5%) 0.083 0.822 (0.603–1.12) 0.214 0.095 0.691 (0.47–1.018) 0.062
Lymph node status (N1, N2 versus N0) <0.001 3.676 (2.701–5.002) <0.001 <0.001 4.26 (2.935–6.184) <0.001

Variables with p value <0.1 in univariate models were analyzed in a multivariate analysis model.

CEA, carcinoembryonic antigen; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; HR, hazard ratio; MIP, micropapillary; VATS, video-assisted thoracic surgery; VPI, visceral pleural invasion.